Furthermore, the increased level of tyrosine phosphatase FAS-associated phosphatase 1 (FAP-1), which targets a β-catenin inhibitor (GSK3β), mediates persistence of CML LSCs [201]. Here, GSK3B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.